Determinants of sub-optimal glycemic control among patients enrolled in a medicine dispensing programme in KwaZulu-Natal : a cohort study, 2018–2021
Loading...
Date
Authors
Johnston, Candice Leigh
Ngassa Piotie, Patrick
Maposa, Innocent
Singh, Sandhya
Kuonza, Lazarus R.
De Voux, Alex
Journal Title
Journal ISSN
Volume Title
Publisher
AOSIS
Abstract
BACKGROUND: The Central Chronic Medicines Dispensing and Distribution (CCMDD)
programme facilitates clinically stable patients to collect their chronic medication from
community-based pick-up points.
AIM: We determined baseline glycaemic control and rates and predictors of becoming suboptimally controlled for type 2 diabetes mellitus (T2DM) CCMDD-enrolled patients.
SETTING: The setting of the study was eThekwini, KwaZulu-Natal, South Africa.
METHODS: We performed a cohort study (April 2018- December 2021). We linked T2DM
CCMDD-enrolled patients to glycated haemoglobin (HbA1c) data from the National Health
Laboratory Service. We selected patients optimally controlled at their baseline HbA1c, with
≥ 1 repeat-test available. We used Kaplan–Meier analysis to assess survival rates and extended
Cox regression to determine associations between time to sub-optimal control (HbA1c > 7%)
and predictors. Adjusted hazard ratios (aHRs), 95% confidence interval (CI), and p-values are
reported.
RESULTS: Of the 41145 T2DM patients enrolled in the CCMDD programme, 7960 (19%) had a
HbA1c result available. Twenty-seven percent (2147/7960) were optimally controlled at their
baseline HbA1c. Of those controlled at baseline, 695 (32%) patients had a repeat test available,
with 35% (242/695) changing to sub-optimal status. The HbA1c testing frequency as per
national guidelines was associated with a lower hazard of sub-optimal glycaemic control
(aHR: 0.46; 95% CI: 0.24–0.91; p-value = 0.024). Patients prescribed dual-therapy had a higher
hazard of sub-optimal glycaemic control (aHR: 1.50; 95% CI: 1.16–1.95; p-value = 0.002) versus
monotherapy.
CONCLUSIONS: The HbA1c monitoring, in-line with testing frequency guidelines, is needed to
alert the CCMDD programme of patients who become ineligible for enrolment. Patients
receiving dual-therapy require special consideration.
CONTRIBUTION: Addressing identified shortfalls can assist programme implementation.
Description
DATA AVAILABITY STATEMENT: Permissions to publish were granted by the NDoH, the NHLS and the CCMDD Programme. The data that support
the findings of this study are available from third parties,
namely, the CCMDD and NHLS. Restrictions apply to the
availability of these data, which were used under licence for
this study. Data are available from the authors with the
permission of the CCMDD and NHLS.
Keywords
CCMDD programme, Glucose control, Survival analysis, eThekwini, Glycaemic control, Central chronic medicines dispensing and distribution (CCMDD), Type 2 diabetes mellitus (T2DM), SDG-03: Good health and well-being, SDG-09: Industry, innovation and infrastructure
Sustainable Development Goals
SDG-03:Good heatlh and well-being
SDG-09: Industry, innovation and infrastructure
SDG-09: Industry, innovation and infrastructure
Citation
Johnston, L.C., Ngassa Piotie, P., Maposa, I., et al. Determinants of sub-optimal glycemic control among patients enrolledin a medicine dispensing programme in KwaZulu-Natal: A cohort study, 2018–2021. African Journal of Primary Health Care and Family Medicine 2024;16(1), a4336.https://doi.org/10.4102/phcfm.v16i1.4336.